Related Experiment Video
Updated: Jun 5, 2026
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Enhanced Demographically Adaptive QT Correction Improves Pediatric Screening for Congenital Long QT Syndrome
Background:
Traditional heart rate (HR) adjusted QT correction (QTc) formulae often fail to eliminate the inverse HR-QT interval relationship, particularly in pediatric patients. In this study, we optimized our previously published adaptive QTc (QTcAd) formula by including additional demographic variables and broadening the pediatric age range. We tested the hypothesis that QTcAd improves congenital long QT syndrome (congenital LQTS) detection performance and reduces erroneous classifications across pediatric cohorts.
Methods:
We retrospectively analyzed 8,306 ECGs from 4,556 cardiovascular disease (CVD)-free pediatric patients. For neonatal patients (1-30 days old), we derived daily QTcAd parameter values. For older patients, we developed regression models to estimate QTcAd parameters (mean Heart Rate (HR) =-15.9ln(days) + 219; |m| = 0.0001(days) + 1, where |m|=absolute HR-QT regression slope). To support LQTS screening, we constructed dynamic QTcAd thresholds by estimating age-specific reference limits. Diagnostic performance was tested in a clinically confirmed LQTS cohort (n=137), and further evaluated in the Pediatric Heart Network (PHN; n=2,394) and Emergency Department (ED; n=2,002) cohorts.
Results:
Using the confirmed LQTS cohort as the event population and the CVD-free cohort as the non-event population, QTcAd demonstrated higher sensitivity than QTcB (92% vs 46.7%). QTcAd maintained high specificity (96.9% vs 98.9%), which resulted in a higher Youden index (0.889 vs 0.456). In the PHN healthy cohort, both QTc formulae classified the majority of individuals as normal (QTcAd 95%; QTcB 98.2%) indicating few false-positives. In the ED cohort, QTcAd reduced borderline/prolonged QTc classifications requiring follow-up, yielding 270 fewer repeat-testing triggers than QTcB. We developed a publicly accessible calculator to compute QTcAd and classify congenital LQTS risk.
Conclusion:
We developed and validated an enhanced QTcAd formula for pediatric patients. QTcAd-based-age-adjusted dynamic thresholding improved performance for congenital LQTS screening, while maintaining high specificity. This reduces false-positive LQTS classifications and repeat ECGs, thereby decreasing unnecessary downstream clinical evaluation.
